Type 1 Diabetes
Conditions
Keywords
Type 1 diabetes, Insulin Pump Therapy
Brief summary
The objective of this feasibility study is to evaluate the efficacy and safety of automated determined Insulin pump settings (i.e., basal plan, correction factor, carbohydrate ration and insulin activity time) using the MD-Logic Pump Advisor in individuals with type 1 diabetes. Study design: Prospective study with two segments: (i) Pilot study, 30 days trial evaluating the MD-Logic pump advisor and (ii), randomized controlled trial (RCT), 30-78 days trial comparing MD-Logic pump advisor to the standard of care of patients with type 1 diabetes. The RCT will be initiated after the pilot segment (including data analysis). The pilot segment will include 15-30 pediatric patients. In the RCT, up to 105 (50 minors under this protocol and 55 adults under a separate protocol)eligible subjects will be enrolled to allow for 92 valuable subjects at the end of the study. The subject population will be randomly assigned 1:1 to either the intervention group or control group. At this pediatric sub study approximately 50 patients will participate and at the separate Adults study additional 55 adult patients will participate.
Detailed description
the MD-Logic Pump Advisor was design by the Diabetes Technology Center, the Institute of Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel. The MD-Logic Pump Advisor learns and adapts the patient's insulin pump settings in order to optimize glucose control. The MD-Logic Pump Advisor needs, as input, sensor readings, insulin delivery and recording of the meals during home care. During collection of the data, the patients are asked to continue their daily routine (no need for special consideration). The present study was designed to test the automatic algorithm that will evaluate and change, when necessary, the patient's insulin pump settings based on prior sensor reading, insulin delivery, and meals data that was collected while the patient is under his regular treatment at home. The objective of this feasibility study is to evaluate the efficacy and safety of automated determined Insulin pump settings (i.e., basal plan, correction factor, carbohydrate ration and insulin activity time) using the MD-Logic Pump Advisor in individuals with type 1 diabetes. Study design: Prospective study with two segments: (i) Pilot study, 30-78 days trial evaluating the MD-Logic pump advisor and (ii), randomized controlled trial (RCT), 30-78 days trial comparing MD-Logic pump advisor to the standard of care of patients with type 1 diabetes. The RCT will be initiated after the pilot segment (including data analysis). The pilot segment will include 15-30 pediatric patients. In the RCT segment, up to 105(50 minors under this protocol and 55 adults under a separate protocol) eligible subjects will be enrolled to allow for 92 valuable subjects at the end of the study. The subject population will be randomly assigned 1:1 to either the intervention group or control group. At this pediatric sub study approximately 50 patients will participate and at the separate Adults study additional 55 adult patients will participate.
Interventions
DEVICEMD Logic Pump Advisor
Insulin pump setting (i.e basal plan, correction factor, carbohydrate ratio and insulin activity time)will be adjusted using the MD-LOgic Pump Advisor
Sponsors
Medtronic
Rabin Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
10 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* Subject with Type 1 diabetes (\> 1yr since diagnosis) * Medetronic ( MiniMed Paradigm 522, 512 , 722 or 712) insulin infusion pump CSII(continuous subcutaneous insulin infusion)therapy for at least 3 months * Age 10-18 years old * HbA1c at inclusion ≥ 6.0% * No concomitant diseases that influence metabolic control * No current use of CGM * Subjects do not participate in any other interventional study * Subject measures SMBG(self-monitoring of blood glucose)at least 4 times a day (before meals and bedtime)
Exclusion criteria
* Known or suspected allergy to trial products * Any significant diseases or conditions including psychiatric disorders and substance abuse that, in the opinion of the investigator, is likely to affect the subject's ability to complete the study, or compromise patient safety * Subject is currently using CGM device * Diabetic ketoacidosis in the past 1 month * Severe hypoglycemia resulting in seizure or loss of consciousness in the month prior to enrollment * Current use of oral glucocorticoids or other medications, which in the judgment of the investigator would be a contraindication to participation in the study * Subject is participating in another drug or device study that could affect glucose measurements or glucose management * Female subject who is pregnant or planning to become pregnant within the planned study duration
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time spent in the normal range | Day 40 | increase in the time spent in the normal range, defined as sensor glucose level within 70-180 mg/dl |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time spent above glucose level of 180 mg/dl | day 40 | time spent above glucose level of 180 mg/dl |
| Time spent below glucose level of 70 mg/dl | day 40 | time spent below glucose level of 70 mg/dl |
| Number of hypoglycemic events below glucose value of 63 mg/dl | day 40 | Number of hypoglycemic events below glucose value of 63 mg/dl |
| Adverse event | day 40 | adverse event |
| Number of iterations required to achieve the maximal time spent in the normal range | day 40 | number of iterations required to achieve the maximal time spent in the normal range |
| Quality of life questionaire | day 40 | quality of life questionaire |
| Number of recommendations the physician would not institute | day 40 | number of MD Logic Pump Advisor recommendations the physician would not institute |
| Number of recommendations for changes in setting per patient and per iPRO wear | day 40 | Number of recommendations for changes in setting per patient and per iPRO wear |
| Glucose variability | day 40 | glucose variability |
Countries
Israel, Slovenia
Outcome results
None listed